About GREB1-like protein
GREB1-like protein (GREB1L) is a protein
from Homo sapiens identified by UniProt accession
Q9C091, 1923 residues long.
MolForge cross-references it against 0 known binders and
105 disease associations.
Target properties
| Protein name | GREB1-like protein |
|---|
| UniProt accession | Q9C091 |
|---|
| Gene | GREB1L |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1923 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (105)
Diseases linked to this target (Open Targets).
- renal hypodysplasia/aplasia 3 · score 0.82
- hearing loss, autosomal dominant 80 · score 0.65
- renal agenesis · score 0.61
- neurodegenerative disease · score 0.52
- Mayer-Rokitansky-Kuster-Hauser syndrome type 1 · score 0.48
- Mayer-Rokitansky-Kuster-Hauser syndrome · score 0.48
- Mayer-Rokitansky-Küster-Hauser syndrome type 2 · score 0.46
- congenital anomaly of kidney and urinary tract · score 0.45
- bilateral renal agenesis · score 0.37
- renal agenesis, unilateral · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9C091-F1 | alphafold | PREDICTED | 71.95 | — |
Amino-acid sequence (1923 residues)
MGNSYAGQLK SARFEEALHN SIEASLRCSS VVPRPIFSQL YLDPDQHPFS SADVKPKVED LDKDLVNRYT QNGSLDFSNN LTVNEMEDDE DDEEMSDSNS PPIPYSQKPA PEGSCTTDGF CQAGKDLRLV SLCMEQIDIP AGFLLVGAKS PNLPEHILVC AVDKRFLPDD HGKNALLGFS GNCIGCGERG FRYFTEFSNH INLKLTTQPK KQKHLKYYLV RSSQGVLSKG PLICWKECRS RQSSASCHSI KPSSSVSSTV TPENGTTNGY KSGFTQTDAA NGNSSHGGKG SASSSTPAHT GNYSLSPRPS YASGDQATMF ISGPPKKRHR GWYPGSPLPQ PGLVVPVPTV RPLSRTEPLL SAPVPQTPLT GILQPRPIPA GETVIVPENL LSNSGVRPVI LIGYGTLPYF YGNVGDIVVS PLLVNCYKIP QLENKDLEKL GLTGSQFLSV ENMILLTIQY LVRLGPDQVP LREEFEQIML KAMQEFTLRE RALQIGAQCV PVSPGQLPWL ARLIASVSQD LVHVVVTQNS LAEGISETLR TLSEMRHYQR LPDYVVVICA SKIRGNEFCV VVLGQHQSRA LAESMLTTSE FLKEISYELI TGKVSFLASH FKTTSLGDDL DKLLEKMQQR RGDSVVTPFD GDLNECVSPQ EAAAMIPTQN LDLDNETFHI YQPQLTVARK LLSQVCAIAD SGSQSLDLGH FSKVDFIIIV PRSEVLVQQT LQRIRQSGVL VDLGLEENGT AHQRAEKYVV RLDNEIQTKF EVFMRRVKQN PYTLFVLVHD NSHVELTSVI SGSLSHSEPS HGLADRVINC REVLEAFNLL VLQVSSFPYT LQTQQSRISS SNEVHWIQLD TGEDVGCEEK LYFGLSEYSK SLQWGITSPL LRCDETFEKM VNTLLERYPR LHSMVVRCYL LIQQYSEALM ALTTMASLRD HSTPETLSIM DDLISSPGKN KSGRGHMLII RVPSVQLAML AKERLQEVRD KLGLQYRFEI ILGNPATELS VATHFVARLK SWRGNEPEEW IPRTYQDLDG LPCIVILTGK DPLGETFPRS LKYCDLRLID SSYLTRTALE QEVGLACCYV SKEVIRGPTV ALDLSGKEQE RAAVSENDSD ELLIDLERPQ SNSSAVTGTS GSIMENGVSS SSTADKSQKQ SLTPSFQSPA TSLGLDEGVS ASSAGAGAGE TLKQECDSLG PQMASSTTSK PSSSSSGPRT LPWPGQPIRG CRGPQAALPP VVILSKAAYS LLGSQKSGKL PSSSSLLPHA DVAWVSSLRP LLNKDMSSEE QSLYYRQWTL ARQHHADYSN QLDPASGTRN FHPRRLLLTG PPQVGKTGSY LQFLRILFRM LIRLLEVDVY DEEEINTDHN ESSEVSQSEG EPWPDIESFS KMPFDVSVHD PKYSLMSLVY TEKLAGVKQE VIKESKVEEP RKRETVSIML TKYAAYNTFH HCEQCRQYMD FTSASQMSDS TLHAFTFSSS MLGEEVQLYF IIPKSKESHF VFSKQGKHLE SMRLPLVSDK NLNAVKSPIF TPSSGRHEHG LLNLFHAMEG ISHLHLLVVK EYEMPLYRKY WPNHIMLVLP GMFNNAGVGA ARFLIKELSY HNLELERNRL EELGIKRQCV WPFIVMMDDS CVLWNIHSVQ EPSSQPMEVG VSSKNVSLKT VLQHIEATPK IVHYAILGIQ KWSSKLTSQS LKAPFSRCHV HDFILLNTDL TQNVQYDFNR YFCEDADFNL RTNSSGLLIC RFNNFSLMKK HVQVGGQRDF IIKPKIMVSE SLAPILPLQY ICAPDSEHTL LAAPAQFLLE KFLQHASYKL FPKAIHNFRS PVLAIDCYLN IGPEVAICYI SSRPHSSNVN CEGVFFSGLL LYLCDSFVGA DLKKFKFLKG ATLCVICQDR SSLRQTIVRL ELEDEWQFRL RDEFQTANSS DDKPLYFLTG RHV
Explore GREB1-like protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets